The currently widely used ICIs are PD-1/PD-L1 inhibitors, which show significant clinical benefits in tumors with a positive expression of PD-L1, but the proportion of this population in some tumors is low, for example, only 20% of breast cancer patients have a positive PD-L1 expression [6]. The gene discussed is CD274; the disease is breast cancer.